| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2801723101016 | 172310101 | ΡΥΘΜΟΝΟΡΜ F.C.TAB 150MG/TAB BTx50 | 3.98 | 4.18 | 5.75 |
| 05/2018 | 2801723102013 | 172310201 | ΡΥΘΜΟΝΟΡΜ F.C.TAB 300MG/TAB BTx50 | 8.13 | 8.53 | 11.75 |
| 05/2018 | 2801723104031 | 172310403 | ΡΥΘΜΟΝΟΡΜ SR PR.CAP 225mg/CAP BTx60 (BLIST 6x10) | 10.79 | 11.32 | 15.60 |
| 05/2018 | 2801723105038 | 172310503 | ΡΥΘΜΟΝΟΡΜ SR PR.CAP 325mg/CAP BTx60 (BLIST 6x10) | 13.25 | 13.90 | 19.15 |
| 05/2018 | 2801723106035 | 172310603 | ΡΥΘΜΟΝΟΡΜ SR PR.CAP 425mg/CAP BTx60 (BLIST 6x10) | 20.68 | 21.69 | 29.89 |
Used to prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. Also used for the treatment of life-threatening documented ventricular arrhythmias, such as sustained ventricular tachycardia.
The electrophysiological effect of propafenone manifests itself in a reduction of upstroke velocity (Phase 0) of the monophasic action potential. In Purkinje fibers, and to a lesser extent myocardial fibers, propafenone reduces the fast inward current carried by sodium ions, which is responsible for the drugs antiarrhythmic actions. Diastolic excitability threshold is increased and effective refractory period prolonged. Propafenone reduces spontaneous automaticity and depresses triggered activity. At very high concentrations in vitro, propafenone can inhibit the slow inward current carried by calcium but this calcium antagonist effect probably does not contribute to antiarrhythmic efficacy.
Symptoms of propafenone overdose (usually most severe within the first 3 hours) may include convulsions (rarely), heartbeat irregularities, low blood pressure, and sleepiness.
Nearly completely absorbed following oral administration (90%). Systemic bioavailability ranges from 5 to 50%, due to significant first-pass metabolism. This wide range in systemic bioavailability is related to two factors: presence of food (food increases bioavailability) and dosage (bioavailability is 3.4% for a 150-mg tablet compared to 10.6% for a 300-mg tablet).
2-10 hours
Naloxone is metabolized in the liver primarily by glucuronide conjugation with naloxone-3-glucuronide as the major metabolite. After an oral or intravenous dose, about 25 to 40% of the drug is excreted as metabolites in urine within 6 hours.
* 252 L